Why Is Biohaven Stock Soaring Wednesday?

Biohaven (BHVN) reported two catalysts this week: a “lucrative” licensing agreement with SK Biopharmaceuticals and a legal victory with Yale University in a trade-secret dispute. The combination of new commercial licensing momentum and strengthened IP position is supportive for the company’s long-term value proposition. While no dollar terms were specified, the legal outcome reduces IP-related overhang and the licensing improves forward revenue prospects.